Most Down Articles

Published in last 1 year| In last 2 years| In last 3 years| All| Most Downloaded in Recent Month | Most Downloaded in Recent Year|

Published in last 1 year

Please wait a minute...


For Selected: Download Citations EndNote Reference Manager ProCite BibTeX RefWorks Toggle Thumbnails

Select

Clinical application of computerized tomography-guided microwave ablation in the treatment of hepatitis B-related hepatocellular carcinoma oligosenterinoma Hu Caixia, Zhao Peng, Liu Bojun, Yang Xiaozhen, Fang Da, Zheng Jiasheng, Zhang Yonghong Electronic Journal of Liver Tumor    2024, 11 (1): 1-3.   Abstract （37）      PDF （1509KB）（27）       Knowledge map    Save Objective: To evaluate the efficacy, safety and application value of microwave ablation for patients with liver cancer associated with hepatitis B and lung metastases in the era of pre-target immunotherapy. Methods: From November 2010 to December 2014,30 patients (24 males and 6 females) with pulmonary metastases were treated by microwave ablation Age ranged from 35 to 74 years, with a median age of 57.1 years. 67 pulmonary metastases were detected by chest CT and 67 lesions were ablated. The diameter of the tumor ranged from 0.5 cm to 4.1 cm in 9 patients with single lesion, 5 patients with 2 lesions and 16 patients with 3 lesions, the average diameter was 1.37 cm. Kaplan-meier method was used to calculate local tumor control rate, median survival time and complications. Results: Microwave ablation was successfully performed 46 times in 67 cases of liver cancer with lung metastases. One to three months after ablation, enhanced CT showed no enhancement in the target area. The complete ablation rate was 100% , and the median survival time was 27.5 months, the main complications included local pain (6 cases) , paroxysmal cough (13 cases) and a small amount of hemoptysis (3 cases) , 10 patients developed mild pneumothorax without special treatment, and 3 patients developed moderate to severe pneumothorax. Immediate closed chest drainage was performed. Conclusion: CT-guided microwave ablation is a safe and effective method for the treatment of lung metastases from hepatitis B-related liver cancer. Reference | Related Articles | Metrics

Select

Research progress on conversion therapy for patients with malignant liver tumors with inadequate remnant liver volume Li Xin, Li Zhiyu Electronic Journal of Liver Tumor    2024, 11 (1): 16-20.   Abstract （32）      PDF （1646KB）（25）       Knowledge map    Save For patients with primary or locally metastatic malignant liver tumors,the only chance for long-term survival is complete resection of the liver tumors. However, post-hepatectomy liver failure(PHLF) remains a major cause of mortality after liver resection,and inadequate future liver remnant has been proven to be a major risk factor for PHLF. Currently,various methods exist for preoperative conversion therapy. Portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy are the two most widely used methods. However, each method has its distinct advantages and disadvantages. With the development of comprehensive treatment for malignant tumors, several treatment methods are under exploration. This study compares different conversion therapy methods,aiming to provide clinical references. Reference | Related Articles | Metrics

Select

Molecular characterization of KRAS G12C mutation in the tumors of digestive system Zhao Tingqi, Dong Lin, Ying Jianming, Li Weihua Electronic Journal of Liver Tumor    2024, 11 (1): 4-8.   Abstract （40）      PDF （1777KB）（23）       Knowledge map    Save Objective: To identified the molecular characteristics of KRAS G12C mutation in the tumors of digestive system. Methods: Data of 1 100 patients diagnosed as digestive malignant tumor in Cancer Hospital of Chinese Academy of Medical Sciences from 2017 to 2022 were collected. The microsatellite status, tumor mutation burden (TMB) and KRAS, NRAS, BRAF and PIK3CA mutations were detected by next-generation sequencing in 1 100 patients with tumors of digestive system, including colorectal adenocarcinoma, duodenal adenocarcinoma, cholangiocarcinoma, gastric adenocarcinoma, ileocecal adenocarcinoma and pancreatic ductal adenocarcinoma. Results: Microsatellite instability-high (MSI-H) tumors were most common in duodenal adenocarcinoma (19%), followed by ileocecal adenocarcinoma (18%) and colorectal adenocarcinoma (10.2%). However, no MSI-H tumors were detected in the 100 cases of pancreatic ductal adenocarcinoma. TMB values also varied among different tumors of digestive system. High-TMB (≥10 mut/Mb) tumors were most common in ileocecal adenocarcinoma (24%), followed by duodenal adenocarcinoma (22%) and gastric adenocarcinoma (18.9%). KRAS mutations were detected in 452 of 1 100 (41.09%) cases, among which the most common tumor was pancreatic ductal adenocarcinoma (85.0%), followed by duodenal adenocarcinoma (56%) and ileocecal adenocarcinoma (53%). However, KRAS mutations were identified in 7.3% of gastric adenocarcinoma. KRAS G12C mutation was detected in 2.82% of all the 1 100 tumors, and only 6.9% (31/452) of all digestive tumors with KRAS mutations among which the most common tumor was ileocecal adenocarcinoma (2/9), followed by duodenal adenocarcinoma (13%) and colorectal adenocarcinoma (8.8%). However, no significant differences in gender, age, MSI and TMB status were observed between patients with KRAS G12C mutation and other KRAS mutation subtypes. Conclusions: Although nearly half of patients with digestive malignancies carry KRAS mutations, but only 6.9% of KRAS-mutant cases harbored KRAS G12C mutation subtype. KRAS G12C mutation was most common in ileocecal cancer, duodenal cancer and colorectal cancer. And no obvious difference in clinical and molecular pathological features compared with other types of KRAS mutations Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 1-13.   Abstract （20）      PDF （1944KB）（21）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (2): 100-103.   Abstract （19）      PDF （5205KB）（20）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (1): 42-46.   Abstract （25）      PDF （6972KB）（20）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Clinical application progress of circulating tumor cells for accurate dynamic monitoring of hepatocellular carcinoma Huang Xiaozhun, Wang Fuzun, Xie Yunliang, Ran Yihong, Xu Lin, Huang Zhangkan, Yin Xin, Bi Xinyu, Che Xu Electronic Journal of Liver Tumor    2024, 11 (1): 21-24.   Abstract （35）      PDF （1596KB）（19）       Knowledge map    Save Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and a major cause of cancer-related death worldwide. There is no ideal biomarker allowing early diagnosis of HCC and tumor surveillance in patients receiving therapy. Circulating tumor cells (CTC) have become a useful tool for diagnosing and monitoring therapeutic responses of different tumors in a non-invasive setting, and have great potential for precision medicine delivery in HCC patients. Based on existing clinical application evidence, this review will discuss the application and research progress of CTC in guiding surgical methods, resection margins, interventional therapy and systematic therapy, and other accurate dynamic monitoring. Reference | Related Articles | Metrics

Select

Research progress of lenvatinib for hepatocellular carcinoma Pei Xirui, Li Xiaohang Electronic Journal of Liver Tumor    2024, 11 (1): 25-29.   Abstract （37）      PDF （1617KB）（19）       Knowledge map    Save Hepatocellular carcinoma is a major challenge affecting global health and has been recognised as a leading cause of death both in China and the world. Due to its insidious, rapidly progressive and highly malignant nature, many patients with hepatocellular carcinoma have already lost their chance of surgery by the time they are diagnosed. Lenvatinib has the ability to inhibit the growth of both tumor cells and tumor angiogenesis, which results in a better effect on patients with unresectable hepatocellular carcinoma and significantly prolongs the overall survival of patients. Therefore, lenvatinib is considered as a first-line target drug for the treatment of unresectable hepatocellular carcinoma. This article presents a systematic review about the research progress of lenvatinib for hepatocellular carcinoma and future perspectives. Reference | Related Articles | Metrics

Select

Efficacy and safety of bevacizumab with nab-paclitaxel and tegafur gimeracil oteracil potassium capsule (S-1) in advanced biliary tract adenocarcinoma Zhang Chao, Sun Yongkun, Su Aijiang, Zhao Jianjun, Zhou Jianguo, Li Zhiyu, Zhou Hua, Zhao Pan, Chen Nan, Liu Na Electronic Journal of Liver Tumor    2024, 11 (2): 61-65.   Abstract （39）      PDF （2199KB）（18）       Knowledge map    Save Objective: To evaluate the efficacy and safety of bevacizumab with nab-paclitaxel and tegafur gimeracil oteracil potassium capsule (S-1) in advanced biliary tract adenocarcinoma patients. Method: Totally 22 stageⅣ biliary tract adenocarcinoma patients were enrolled in this single arm, single center prospective phaseⅡ study. Patients were treated with bevacizumab at a dose of 5 mg/kg on day 1, nab-paclitaxel at a dose of 150 mg/m2 on day 1 and S-1, 40 to 60 mg bid/day on days 1-10 of a 14-day cycle. Treatments were repeated until disease progression or unacceptable toxicity occurred. The primary endpoint was objective response rate (ORR). The secondary endpoints were median progression-free survival (PFS), disease control rate (DCR), and adverse events (AEs). Result: The number of patients enrolled were 22, and 21 patients were evaluated for efficacy, with a median of 6 cycles of treatment and a median of 2 lines of treatment. A total of 9 patients achieved partial response (PR) with an ORR of 42.9%(9/21), DCR was 85.7%(18/21). 3 progressive disease was observed. The median PFS were 8 months (95% confidence interval [95%CI]: 4.5~11.5). The incidence of grade 3 treatment-related adverse events in 22 patients was 68.2%(15/22), and there were no grade 4 treatment-related adverse events. The most common grade 3 or 4 toxicities were neutropenia (18.1%), Thrombocytopenia in 2 cases (9.1%), gastrointestinal reaction in 2 cases (9.1%), increased total bilirubin (TBIL)/direct bilirubin (DBIL) in 1 case (4.5%), anemia in 1 case (4.5%), others including neurotoxicity, elevated aminotransferase, bleeding, diarrhea, fatigue, elevation of blood pressure, proteinuria, etc., were grade 1 to 2. During treatment, 4 cases (18.1%) were combined with infection, 3 cases stopped treatment due to adverse events, and there were no treatment-related deaths. Conclusion: The combination of bevacizumab with nab-paclitaxel and S-1 showed explicit antitumor activities and favorable safety profile in advanced biliary tract adenocarcinoma patients, which has good clinical therapeutic value. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (1): 47-49.   Abstract （27）      PDF （1635KB）（16）       Knowledge map    Save Related Articles | Metrics

Select

A Meta-analysis of the curative effect and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of large liver cancer Li Mei, Qiao Bei, Zhang Zhihao Electronic Journal of Liver Tumor    2024, 11 (1): 9-15.   Abstract （24）      PDF （7001KB）（15）       Knowledge map    Save Objective: Through Meta-analysis, compared with transcatheter arterial chemoembolization (TACE) alone, to analyze the curative effect and safety of TACE combined with radiofrequency ablation (RFA) in treating large liver cancers. Method: According to the Meta-analysis process, the relevant domestic and foreign related databases such as PubMed, Embase, Seer, Cochrane Library, CNKI, Wanfang Medical Network, VIP, China Biomedical Literature Database were searched with defined search terms. The search period was January 2003 to June 2023. Randomized controlled clinical studies on the efficacy and safety of TACE+RFA versus TACE alone in the treatment of large liver cancer were screened and included. The quality of the included studies was evaluated and Meta-analysis was performed using RevMan5.4 software. Result:Finally, A total of 16 papers were included, involving 1 175 patients, including 587 cases in the TACE+RFA group and 588 cases in the TACE alone group. The results of Meta-analysis indicated that: compared with the TACE alone group, the objective response rate (ORR) [relative risk (RR)=1.46, 95% confidence interval (95%CI): 1.35-1.59, P<0.000 01], disease control rate (DCR) (RR=1.17, 95%CI: 1.12-1.22, P<0.000 01), 1-year survival rate (RR=1.39, 95%CI: 1.24-1.55, P<0.000 01), 2-year survival rate (RR=1.79, 95%CI: 1.38-2.32, P<0.000 1) and 3-year survival rate (RR=3.20, 95%CI: 1.25-8.20, P=0.02) of TACE+RFA group were better than those of simple TACE group, and the difference was statistically significant. There was no significant difference in the common adverse reactions between the two groups. Conclusion: Compared with TACE alone, TACE+RFA can improve the short-term efficacy and the long-term survival rate of large liver cancer patients, and does not increase the occurrence of adverse reactions. Reference | Related Articles | Metrics

Select

Prognosis and risk factors of different recurrence patterns after hepatectomy for colorectal liver metastasis Chen Hanwei, Li Lei Electronic Journal of Liver Tumor    2024, 11 (2): 27-32.   Abstract （36）      PDF （3700KB）（14）       Knowledge map    Save Objective: To study the prognostic differences and risk factors of different recurrence patterns after hepatectomy for colorectal liver metastasis. Methods: The general data, clinical data and follow-up data of patients with colorectal liver metastasis who underwent hepatectomy in the Department of General Surgery of Peking University Third Hospital from January 2009 to February 2023 were collected. Kaplan-Meier curve was used to analyze the survival differences between different recurrence times and different recurrence sites. The maximally selected test was used to find the optimal cut-off value of recurrence time for distinguishing the survival after recurrence. Logistic regression analysis were used to analyze the risk factors of early recurrence. Results: A total of 281 patients met the inclusion and exclusion criteria. There were statistically significant differences in mortality and overall survival between patients with and without postoperative recurrence (P=0.001). The optimal cut-off value for distinguishing early and late recurrence was 12 months (P=0.001). There was a statistically significant difference in the post-recurrence survival between patients with early recurrence and late recurrence (P=0.001 1). There was a statistically significant difference in the post-recurrence survival between different recurrence sites (P=0.002 3), and the prognosis of patients with the first recurrence site in the lung was the best. Logistic regression analysis showed that patients with positive lymph node metastasis of primary tumor (OR=2.294, 95%CI:1.171-4.496, P=0.019), preoperative CEA≥5.31 ng/ml (OR=2.160, 95%CI:1.001-4.660, P=0.049 8) and preoperative CA19-9≥ 40.52 U/ml (OR=2.210, 95%CI:1.030-4.741, P=0.042) were at high risk of early recurrence after surgery. Conclusions: The recurrence within 12 months and extrapulmonary recurrence is associated with poor prognosis. The risk factors for early recurrence include positive lymph node metastasis of primary tumor, preoperative CEA≥5.31 ng/ml and preoperative CA19-9≥ 40.52 U/ml. Patients with related risk factors should be actively reviewed and monitored. Reference | Related Articles | Metrics

Select

Global liver and gallbladder cancer incidence and mortality in 2022 and projections to 2050 Liu Manqi, Xu Mengyuan, Shan Tianhao, Zhao Hong, Zeng Hongmei, Cai Jianqiang Electronic Journal of Liver Tumor    2024, 11 (2): 53-60.   Abstract （30）      PDF （2821KB）（12）       Knowledge map    Save Objective: To analyze the global epidemiological profiles of liver and gallbladder cancer in 2022, and project the global burden of cancer incidence and mortality until 2050. Methods: Based on the GLOBOCAN 2022 database, we analyzed the global burden of liver and gallbladder cancer in 2022 and the projected disease burden in 2050. We calculated age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) by using Segi's world standard population structure data. We estimated the future number of cases and deaths by 2050 based on world population prospects. Results: In 2022, there were an estimated 866,136 new cases and 758,725 deaths from liver cancer, corresponding to ASIRs and ASMRs of 8.6 per 100,000 and 7.4 per 100,000, respectively. There were an estimated 122,491 new cases and 89,055 deaths from gallbladder cancer, corresponding to ASIRs and ASMRs of 1.2 per 100,000 and 0.83 per 100,000, respectively. Incidence and mortality rates of liver cancer were higher in males than in females across different age groups, and gallbladder cancer displayed higher rates among females compared to males. The country with the highest ASIR and ASMR for liver cancer was Mongolia. For gallbladder cancer, Bolivia reported the highest ASIR and ASMR. By 2050, the annual number of new cases and deaths from liver cancer will increase to 1,564,034 (an 80.6 percent increase from the year 2022) and 1,420,926 (an 87.3 percent increase), respectively. The annual number of new cases and deaths from gallbladder cancer will increase to 235,096 (a 91.9 percent increase from the year 2022) and 176,725 (a 98.4 percent increase), respectively. Africa has the largest increase in both projected new cases and deaths from liver and gallbladder cancer globally in 2050. Conclusions: Inequities in liver and gallbladder disease burden persist worldwide. Regions such as Asia and Africa, as well as countries such as Mongolia and Bolivia, which face heavy disease burden and rising incidence rates, must prioritize the establishment of cancer control initiatives. Reference | Related Articles | Metrics

Select

Research progress in the liquid biopsy in hepatocellular carcinoma Liang Renshan, Zhang Yu, Chen Zutao, Feng Tingting Electronic Journal of Liver Tumor    2024, 11 (1): 30-33.   Abstract （28）      PDF （1660KB）（11）       Knowledge map    Save At present, primary hepatocellular carcinoma ranks fourth common malignant tumor and second tumor cause of death in China, seriously threatening the pubic life and health.Because of its hidden incidence and non-specific clinical manifestations, the early diagnosis rate of primary liver cancer is low.When liver cancer is found,the condition often have progressed to the advanced stage and the prognosis is very poor.Therefore, modern medicine there is an urgent need for new detection methods to early diagnosis, real-time monitoring and effective treatment of liver cancer."Liquid biopsy" is one of the new detection methods.Many studies have shown that liquid biopsy is of great significance in the early diagnosis, targeted treatment, metastasis, recurrence and prognostic evaluation of liver cancer. The purpose of this review is to briefly introduce the research progress of liquid biopsy in hepatocellular carcinoma. Reference | Related Articles | Metrics

Select

Effect of targeted nursing management on patients with liver cancer after radiotherapy Du Mengya, Chen Peijuan, Sun Jingyuan Electronic Journal of Liver Tumor    2024, 11 (1): 34-37.   Abstract （32）      PDF （1597KB）（10）       Knowledge map    Save Objective: To explore the intervention effect of targeted nursing in radiotherapy of liver cancer patients. Methods: From October 2017 to October 2019, 208 patients with liver cancer undergoing radiotherapy in our hospital were selected and randomly divided into control group (106 cases) and experimental group (102 cases). The two groups were given targeted nursing and routine nursing respectively. Baseline data were compared between the two groups, as well as visual analog pain scores, anxiety and depression scores, quality of life scores, complication rate, compliance, and satisfaction with care. Results: There was no significant difference in visual analog pain scores, anxiety and depression scores, and quality of life scores between the two groups before the targeted intervention (all P> 0.05). After 3 months of care, the visual analog pain, anxiety, depression and quality of life were higher than the control group (all P<0.05); the complication rate was lower than the control group (9.8% vs 30.2%, P<0.05), and the compliance was better than the control group (96.07% vs 84.91%, P<0.05); the nursing satisfaction was higher than the control group (all P<0.05). Conclusion: Targeted nursing can reduce the complications of patients with liver cancer radiotherapy, improve the overall satisfaction of patients. Reference | Related Articles | Metrics

Select

The effects of acceptance and commitment therapy psychological intervention on negative emotion and treatment compliance of patients with primary liver cancer Sun Yali, Tong Huanqing, Yuan Pomian, Liu Le, Wu Na, Zhou Kan, Zhai Jiuling Electronic Journal of Liver Tumor    2024, 11 (1): 38-41.   Abstract （21）      PDF （1508KB）（10）       Knowledge map    Save Objective: To investigate the effects of acceptance and commitment therapy (ACT) psychological intervention on negative emotion and treatment compliance of patients with primary liver cancer. Method: Totally 100 patients were choose with primary liver cancer in our department for the observation object from May 2019 to April 2021. According to the admission time order using a random digital table to divide the patient into 50 cases of intervention group and control group. And the control group were given conventional care, intervention group implements ACT psychological intervention on the basis of regular care. Compared the results of the two groups. Result: Anxiety and self-evaluation scale (SAS) rating / depression self-evaluation schedule (SDS) score of the intervention group is lower than that of the control group [96.0%(48/50) vs 78.0%(39/50), χ2=5.315, P<0.05]. The treatment compliance of the intervention group was higher than that of the control group [(49.3±1.7) vs (53.0±1.6), t=11.525, P<0.001; (44.2±1.5) vs (48.9±1.5), t=15.969,P<0.001]. Conclusion: Application of ACT psychological intervention, can reduce negative emotion of patients with primary liver cancer to improve their treatment compliance, reduce patient psychological pressure, thereby improving the survival quality of patients. Reference | Related Articles | Metrics

Select

The prognostic value of preoperative platelet to neutrophil ratio in colorectal cancer patients with resectable synchronous liver metastases Zhang Jixin, Wu Liang, Wu Xueliang, Wang Likun, Ma Hongqing, Han Lei Electronic Journal of Liver Tumor    2024, 11 (2): 66-71.   Abstract （20）      PDF （2538KB）（10）       Knowledge map    Save Objective: To investigate the prognostic value of preoperative serum platelet to lymphocyte ratios (PLR) in colorectal cancer patients with synchronous liver metastases. Methods: The 74 patients clinicopathological data of in colorectal cancer patients with synchronous liver metastases who underwent liver resection in First Affiliated Hospital of Hebei North University were collected retrospectively. The X-tile software was used to calculate the best cut-off value of PLR toward prognosis, and the patients were divided into low PLR group (n=31) and high PLR group (n=43) according to the aforementioned cut-off value. Differences in general clinicopathological data and prognosis of the two group patients were investigated. Results: The best cut-off for PLR prognosis was 188, PLR≥188 was the high PLR group and PLR<188 was the low PLR group. Compared with patients in the low PLR group, the tumor stage of the high PLR group was later, the lymph node metastasis rate was higher, and the number of liver metastases was more (all P<0.05). The median survival time of patients in the high PLR group and the low PLR group were 33 months and 11 months (P=0.001), respectively. The Cox model multivariate analysis showed that pT staging (HR=2.199, 95%CI: 1.156-4.182, P=0.016), carcinoembryonic antigen ≥3.4 ng/ml (HR=1.834, 95%CI: 1.079-3.117, P=0.025), and PLR≥188 (HR=1.885, 95%CI: 1.022-3.477, P=0.042) were independent risk factors for the colorectal cancer patients with synchronous liver metastases. The prognostic prediction model was constructed according to the results of the survival analysis, and the validity curve and the receiver operation characteristic curve showed good model fit and accuracy. Conclusions: Preoperative PLR is closely related to the poor prognosis of colorectal cancer patients with synchronous liver metastases. Patients with preoperative PLR≥188 have a worse prognosis. The survival prediction models is constructed based on PLR, T stage and carcinoembryonic antigen have high accuracy and can be used to guide clinical practice. Reference | Related Articles | Metrics

Select

Research progress in the treatment of unresectable intrahepatic cholangiocarcinoma Zhang Yongqi, Li Zhao Electronic Journal of Liver Tumor    2024, 11 (2): 89-93.   Abstract （14）      PDF （1919KB）（9）       Knowledge map    Save Intrahepatic cholangiocarcinoma (ICC) is the second most common primary tumor in the liver, and radical surgical resection is currently the main way to cure ICC. But ICC has an insidious onset, rapid progression, and many have lost the opportunity for radical surgery when clinically found. Chemotherapy regimens such as gemcitabine combined with cisplatin are often used clinically to treat unresectable ICC, but the efficacy is often not satisfactory. The emergence of new therapies such as targeted therapy and immunotherapy has brought a new direction for the treatment of unresectable ICC. Through the study of the mechanism of ICC tumorigenesis, researchers have discovered potential targets for the treatment of ICC, and clinical drug trials for targets such as EGFR, VEGF, FGFR2, HER2, IDH1/2, BRAF, NTRK, MEK1/2 and other targets have made good progress. Trials of immune checkpoint inhibitors have also shown good efficacy in patients with ICC. The combination of the above therapies can also enable some patients to achieve tumor reduction and obtain surgical opportunities. This article reviews the recent research progress of treatment for unresectable ICC, in order to provide new ideas for the treatment of ICC. Reference | Related Articles | Metrics

Select

Study on the development track of early fatigue after liver transplantation Xi Shuangmei, Zhang Lili, Gu Yanmei, Guo Huimin, Liu Xin, Zheng Yulin, Jin Boxun, Li Guangming Electronic Journal of Liver Tumor    2024, 11 (2): 94-99.   Abstract （22）      PDF （2176KB）（9）       Knowledge map    Save Objective: To explore the development track of early fatigue after liver transplantation and its influencing factors. Methods: 96 liver transplant patients who were followed up in the liver transplant center of our hospital from January 2019 to March 2023 were selected as the research objects. Fatigue assessment scale (FAI) was used to evaluate the fatigue of patients at 1 week, 2 weeks, 1 month, 3 months and 6 months after liver transplantation, and growth mixed model (LGMM) was used to analyze and identify the early fatigue development track of patients after liver transplantation. The general data, social support and psychological state of patients were collected, and the influencing factors of patients' early fatigue development track were analyzed by multi-classification Logistic regression. Results: During the 6-month follow-up, there were 91 patients with complete follow-up data of FAI scale, and finally 91 patients were included. LGMM analysis showed that the early fatigue development trend of patients after liver transplantation was divided into three types, namely, descending group(n=36), stable group(n=34) and ascending group(n=21). The fatigue development of all three groups had a time effect. The FAI score of descending group decreased significantly with time, while that of stable group did not change significantly with time, while that of ascending group increased significantly with time. Logistic regression analysis showed that age, anxiety, depression, sleep status and social support level were the influencing factors of early fatigue development after liver transplantation (P<0.05). Conclusion: The development track of early fatigue in patients after liver transplantation is heterogeneous, and there are different types of development trends, among which age, anxiety, depression, sleep state and social support level are the influencing factors. Reference | Related Articles | Metrics

Select

Expression and clinical significance of transmembrane protein 132A in liver cancer based on bioinformatics Zhao Hangqi, Ma Xiaowen, Zhang Tian'ai, Li Baifeng Electronic Journal of Liver Tumor    2024, 11 (3): 33-41.   Abstract （16）      PDF （9212KB）（9）       Knowledge map    Save Objective: To explore the expression pattern and clinical significance of transmembrane protein 132A (TMEM132A) in liver cancer based on public databases. Methods: The Cancer Genome Atlas and GSE14520, GSE60502 of Gene Expression Omnibus was used to analyze the mRNA level of TMEM132A in liver cancer and adjacent tissues, the promoter methylation level, and the correlation with clinical factors. The immunohistochemical results of TMEM132A in tissues were obtained through HPA database. Kaplan-Meier method was used to explore the correlation between TMEM132A and the prognosis of patients. Receiver operating characteristic curve was used to explore whether TMEM132A could accurately diagnose patients. The drug sensitivity of TMEM132A to chemotherapy drugs was predicted by cancer drug sensitivity genomics. Immune analysis of TEME132A was performed by single-sample GSEA, TIMER, STORMAL SCORE and immune checkpoint heatmap. Linkedomics website was used to perform gene set enrichment analysis for differential genes of TMEM132A. The STRING database was used to predict the interacting proteins of TMEM132A. Results: The expression of MEM132A in HCC tissues was significantly higher than that in adjacent tissues (P<0.05), and it was located in the cytoplasm and cell membrane. The high expression of TMEM132A was positively correlated with tumor stage, grade, AFP level and body weight. High expression of TMEM132A indicates poor prognosis and can be used as an accurate diagnostic indicator. TMEM132A is sensitive to a variety of chemotherapy drugs and infiltrated by a variety of immune cells, which can be used as a research target for drug therapy and immunotherapy. The promoter methylation level of TMEM132 was significantly decreased in cancer tissues. TMEM132A affects cell adhesion, fatty acid metabolism and other signaling pathways. Conclusion: TMEM132A is highly expressed in HCC and positively correlated with poor prognosis. Reference | Related Articles | Metrics